retatrutide ly3437943 triple agonist gip glp-1 glucagon Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide: How Triple GLP-1/GIP/Glucagon Receptor

Cortes :Writing review & editing, Investigation, Formal analysis, Conceptualization

And only around 10% of people were able to maintain all the weight theyve lost

References Creatine Supplementation and Exercise Performance Journal of the International Society of Sports Nutrition Coenzyme Q10 and Mitochondrial Function in Human Health Frontiers in Physiology Magnesium Fact Sheet for Health Professionals National Institutes of Health Office of Dietary Supplements N-Acetylcysteine: Pharmacology and Clinical Applications Pharmacology and Therapeutics The Metabolism and Function of Alpha-Lipoic Acid Journal of Biological Chemistry Vitamin C and Collagen Synthesis in Connective Tissue National Institutes of Health Zinc and Its Biological Roles in Enzymatic Activity FDA Disclaimer Statements made within this website have not been evaluated by the Food and Drug Administration

A heptapeptide studied for anxiolytic and cognitive effects without the sedation or dependence associated with benzodiazepines

My first month went really well